DOCSLIB.ORG

Open Full Page

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Open Full Page 2328 A bifunctional colchicinoid that binds to the androgen receptor Nima Sharifi,1,3 Ernest Hamel,2 Markus A. Lill,4 activity of this compound increases cytoplasmic AR levels Prabhakar Risbood,5 Charles T. Kane, Jr.,6 in prostate cancer cells. Finally, we found that this com- Md Tafazzal Hossain,6 Amanda Jones,7 pound has greater toxicity against androgen-independent James T. Dalton,7 and William L. Farrar1 prostate cancer cells than the combination of colchicine and nilutamide. Together, these data point to several 1Cancer Stem Cell Section, Laboratory of Cancer Prevention, ways of inhibiting AR function in CRPC. [Mol Cancer Ther National Cancer Institute at Frederick, Center for Cancer 2007;6(8):2328–36] Research, and 2Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Introduction National Cancer Institute, Frederick, Maryland; 3Medical Oncology Branch, Center for Cancer Research, National Cancer Prostate cancer is the leading cause of nonskin malignancy Institute, Bethesda, Maryland; 4Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, in men (1). Growth and survival of prostate cancer is West Lafayette, Indiana; 5Drug Synthesis and Chemistry Branch, dependent on androgens and androgen receptor (AR) Division of Cancer Treatment and Diagnosis, National Cancer signaling. Therefore, advanced disease is generally first Institute, Rockville, Maryland; 6Starks Associates, Inc., Buffalo, treated with androgen deprivation therapy by medical or 7 New York; and Division of Pharmaceutics, College of Pharmacy, surgical castration (2). Metastatic disease almost always Ohio State University, Columbus, Ohio overcomes androgen deprivation and progresses as cas- trate-resistant prostate cancer (CRPC). A wealth of evi- Abstract dence suggests that CRPC is still reliant on AR for tumor Castrate-resistant prostate cancer (CRPC) continues to be cell survival and disease progression (3). In the castrate- dependent on the androgen receptor (AR) for disease resistant setting, AR is reactivated by a variety of progression. We have synthesized and evaluated a novel mechanisms that include but are not limited to AR gene compound that is a conjugate of colchicine and an AR amplification and other mechanisms of increasing AR antagonist (cyanonilutamide) designed to inhibit AR expression and ligand-independent activation by growth function in CRPC. A problem in multifunctional AR-binding factors and cytokines (4). Furthermore, a subset of compounds is steric hindrance of binding to the embedded androgen-responsive genes are reactivated in CRPC (5), hydrophobic AR ligand-binding pocket. Despite the bulky and prostate-specific antigen declines will often occur with side chain projecting off of the AR-binding moiety, this secondary hormonal therapies that also target AR (6). novel conjugate of colchicine and cyanonilutamide binds Together, this evidence suggests that AR is still a valid target in CRPC, and compounds that have novel AR- to AR with a Ki of 449 nmol/L. Structural modeling of this compound in the AR ligand-binding domain using a targeting mechanisms should provide new avenues for combination of rational docking, molecular dynamics, and prostate cancer therapy (7). steered molecular dynamics simulations reveals a basis for The rationale for the design and synthesis of a compound how this compound, which has a rigid alkyne linker, is able that has independent tubulin-binding and AR-binding to bind to AR. Surprisingly, we found that this compound moieties is 4-fold. First, many tubulin-binding drugs are also binds to tubulin and inhibits tubulin function to a used for cancer chemotherapy. In fact, the only form of greater degree than colchicine itself. The tubulin-inhibiting chemotherapy shown to prolong survival for metastatic prostate cancer patients is a tubulin-binding drug (8, 9). Addition of an AR-binding moiety to a therapeutic agent could selectively target AR-expressing prostate cancer cells, with minimal impact on cells that do not express AR. Received 3/7/07; revised 5/14/07; accepted 6/15/07. Second, the nuclear import of steroid hormone receptors is Grant support: Intramural Research Program of the NIH and the Center for Cancer Research, National Cancer Institute, and in part with Federal funds a microtubule-dependent process (10). The use of colchi- from the National Cancer Institute, NIH, under contract N02-CM-52209. cine, which only binds to the soluble tubulin heterodimer The costs of publication of this article were defrayed in part by the and disrupts tubulin polymerization, may thereby inhibit payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to the nuclear import of AR. Third, independent AR-binding indicate this fact. and tubulin-binding moieties in a single compound would Requests for reprints: Nima Sharifi or William L. Farrar, Room 21-81, potentially result in concomitant AR and tubulin binding, Cancer Stem Cell Section, Laboratory of Cancer Prevention, National thereby anchoring AR to tubulin. Thus, the bound AR Cancer Institute at Frederick, Building 560, Frederick, MD 21702. Phone: 301-451-4982; Fax: 301-846-7042. E-mail: [email protected] would remain in the cytoplasm. However, a difficulty is or [email protected] preservation of binding to the hydrophobic AR ligand- Copyright C 2007 American Association for Cancer Research. binding domain, in which androgen ligands are completely doi:10.1158/1535-7163.MCT-07-0163 buried (11). Adding a linker or a bulky moiety to an AR Mol Cancer Ther 2007;6(8). August 2007 Downloaded from mct.aacrjournals.org on September 25, 2021. © 2007 American Association for Cancer Research. Molecular Cancer Therapeutics 2329 ligand could therefore easily lead to loss of AR-binding TLC was done on Merck 60 F254 silica gel glass plates. activity. Fourth, if AR ligand-binding activity can be Elemental analyses were done by Atlantic Microlabs. conserved with a compound that has a linker that extends Melting points are uncorrected. Unless stated, all solvents outside the ligand-binding domain, this could disrupt and reagents were purchased from commercial sources and binding to steroid receptor coactivators that are required used without further purification. for AR function (12). Benzonitrile, 4-[3-(4-Hydroxy-2-Butynyl)-4,4-Dimethyl- Colchicine, thiocolchicine, and combretastatin A-4 all 2,5-Dioxo-1-Imidazolidinyl]-2-(Trifluoromethyl)- (2). To bind to a common site on tubulin referred to as the 1 (ref. 15; 3.90 g, 13.1 mmol) in dimethylformamide colchicine site (13). Studies of the structure-activity rela- (DMF; 60.0 mL) was added cesium carbonate (3.85 g, 11.8 tionship of colchicine suggest that the C7 acetamido group mmol) and a solution of 4-chloro-2-butyn-1-ol (3.60 g, 34.4 can be modified while preserving tubulin-binding activity mmol) in DMF (5.0 mL). After 3 h at room temperature, (14). We therefore chose this site for one end of the linker. the mixture was filtered. The filtrate was diluted with Cogan and Koch (15) used a rigid alkyne linker with a EtOAc (500 mL), washed with water (1.2 L), then dried N cleavable salicylamide -Mannich base in doxorubicin- (MgSO4) and concentrated. The white solid was dried targeting for prostate cancer. Although we used the alkyne under reduced pressure to give 2 (2.85 g, 59%). 1HNMR N y J moiety, we excluded the salicylamide -Mannich base and (500 MHz, DMSO-d6): 8.32 (d, 1H, = 8.4 Hz); 8.20 (d, 1H, selected a noncleavable linker to allow for the possibility of J = 1.6 Hz); 8.06–8.04 (dd, 1H, J = 1.7, 8.4 Hz); 5.16–5.14 concomitant AR and tubulin binding. We constructed a (t, 1H, J = 5.9 Hz); 4.30 (s, 2H); 4.08–4.07 (m, 2H); 1.54 linker with sufficient length to extend the colchicine moiety (s, 6H). Mass spectroscopy: electrospray (positive ion): m/z outside the AR ligand-binding domain. Cyanonilutamide is calculated for C17H14F3N3O3 = 365; found: (relative + structurally similar to nilutamide and has a slightly higher intensity) 383 [(M + NH4) , 100%]. HPLC: retention time affinity for the AR than does nilutamide (15). 13.879 min with 100% peak area [Luna C18, 4.6  250 mm, A These considerations led us to synthesize acetamide, 2-[4- 5 . Mobile phase: A = 0.05 mol/L H3PO4 buffer (pH, 3); [3-[(4-cyano-3-trifluoro-methyl)phenyl]-5,5-dimethyl-2,4- B = acetonitrile + 1% water. Linear gradient = 95% A; 70% dioxoimidazol-idin-1-yl]-but-2-ynyloxy]-N-[(7S)-5,6,7,9-tet- A; 100% B; 95% A]. rahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7- Acetic Acid, 2-[4-[3-[(4-Cyano-3-Trifluoromethyl)- yl], and will hereafter refer to this compound as CCN, for Phenyl]-5,5-Dimethyl-2,4-Dioxoimidazolidin-1-yl]But-2- colchicine-cyanonilutamide. Here, we describe the proper- ynyloxy]-Methyl Ester (3). A mixture of 2 (1.80 g, 4.93 ties of CCN and the structural basis for how it binds AR. mmol) and thallium ethoxide (349 AL, 4.93 mmol) in CCN binds to tubulin and inhibits tubulin assembly with CH3CN (17.0 mL) was stirred for 1 h at ambient greater potency than colchicine and has activity that is temperature and then concentrated to dryness. The powder comparable to the more potent thiocolchicine (13). Despite was dissolved in DMF (17.0 mL), and methyl bromoacetate the hydrophobic binding pocket of the AR ligand-binding (3.8 g, 24.8 mmol) was added. The mixture was heated at domain and the relatively bulky nature of colchicine, CCN 60jC for 3 h and then cooled to room temperature, and still retains AR-binding activity. We determined the water (50 mL) was added. This was extracted with diethyl  structural basis of binding to the AR ligand-binding ether (4 100 mL), dried (MgSO4), and concentrated.
Load more

Recommended publications
  • Determinants of Anti-Vascular Action by Combretastatin A-4 Phosphate: Role of Nitric Oxide
    British Journal of Cancer (2000) 83(6), 811–816 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1361, available online at http://www.idealibrary.com on Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide CS Parkins1, AL Holder1, SA Hill1, DJ Chaplin1,2 and GM Tozer1 1Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK; 2Aventis Pharma, Centre de Reserche de Vitry-Alfortville, 13 quai Jules Guesole, BP14, 94403 Vitry sur seine, Cedex, France Summary The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma SaS. The functional vascular volume, assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumour types, although the degree of reduction was very different in the two tumours. The SaS tumour, which has a higher nitric oxide synthase (NOS) activity than the CaNT tumour, showed ~10-fold greater resistance to vascular damage by CA-4-P. This is consistent with our previous findings, which showed that NO exerts a protective action against this drug. Simultaneous administration of CA-4-P with a NOS inhibitor, Nω-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumour types. Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects. Following treatment with CA-4-P, neutrophil infiltration into the tumours, measured by myeloperoxidase (MPO) activity, was significantly increased.
    [Show full text]
  • Combretastatin A-4 Analogues with Benzoxazolone Scaffold: Synthesis, Structure and Biological Activity
    European Journal of Medicinal Chemistry 120 (2016) 121e133 Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Research paper Combretastatin A-4 analogues with benzoxazolone scaffold: Synthesis, structure and biological activity Mariana S. Gerova a, Silviya R. Stateva b, Elena M. Radonova b, Rositsa B. Kalenderska b, Rusi I. Rusew c, Rositsa P. Nikolova c, Christo D. Chanev a, Boris L. Shivachev c, * Margarita D. Apostolova b, Ognyan I. Petrov a, a University of Sofia “St. Kliment Ohridski”, Faculty of Chemistry and Pharmacy, Department of Pharmaceutical and Applied Organic Chemistry, 1 James Bourchier Blvd, 1164 Sofia, Bulgaria b Bulgarian Academy of Sciences, Institute of Molecular Biology, Acad. G. Bonchev Str., bl. 21, 1113 Sofia, Bulgaria c Bulgarian Academy of Sciences, Institute of Mineralogy and Crystallography, Acad. G. Bonchev Str., bl. 107, 1113 Sofia, Bulgaria article info abstract Article history: In order to design and synthesize a new class of heterocyclic analogues of natural combretastatin A-4 and Received 15 February 2016 its synthetic derivative AVE8062, the benzoxazolone ring was selected as a scaffold for a bioisosteric Received in revised form replacement of the ring B of both molecules. A library of 28 cis- and trans-styrylbenzoxazolones was 27 April 2016 obtained by a modified Wittig reaction under Boden's conditions. Structures of the newly synthesized Accepted 5 May 2016 compounds bearing the 3,4,5-trimethoxy-, 3,4-dimethoxy-, 3,5-dimethoxy-, and 4-methoxystyryl frag- Available online 6 May 2016 ment at position 4, 5, 6 or 7 of benzoxazolone core were determined on the basis of spectral and X ray data.
    [Show full text]
  • In Vivo Antitumour Effect of Combretastatin A-4 Phosphate Added to Fractionated Irradiation
    ANTICANCER RESEARCH 26: 307-310 (2006) In Vivo Antitumour Effect of Combretastatin A-4 Phosphate Added to Fractionated Irradiation B. AHMED1, W. LANDUYT1, A.W. GRIFFIOEN2, A. VAN OOSTEROM1, W. VAN DEN BOGAERT1 and P. LAMBIN1,3 1Laboratory Experimental Radiobiology/LEO, Catholic University Leuven (KUL), UZ Gasthuisberg, B-3000 Leuven, Belgium; 2Angiogenesis Laboratory, Department of Pathology, University Hospital Maastricht, Maastricht; 3MAASTRO Lab., GROW Research Institute, University Maastricht, Maastricht, The Netherlands Abstract. Background: The study aimed at evaluating the disrupt the tubulin cytoskeleton of rapidly proliferating and potential benefit from a combination of fractionated ionising immature tumour endothelial cells (3-5). The lead radiation with the vascular-targeting compound combretastatin compound in this class, combretastatin A-4 phosphate (CA- A-4 phosphate (CA-4-P). Materials and Methods: Syngenic rat 4-P), has completed phase I clinical trials (6, 7) and entered rhabdomyosarcoma (R1), growing subcutaneously, was treated a phase II trial. Preclinical studies, involving various rodent at 2 different sizes: either small (2±0.5 cm3) or large tumour types, have demonstrated a rapid and strong (10.94±0.6 cm3). Localised fractionated irradiation of the reduction in blood flow and vessel occlusion when a single tumours (5 x 3 Gy) in 5 days was followed 1 day later by an non-toxic dose of CA-4-P was used (8). Although severe intraperitoneal CA-4-P treatment (25 mg/kg). Results: The induction of necrosis was observed, little or no retardation combined treatment of only large tumours resulted in a small of tumour growth was measured (9, 10). However, a additional growth delay when compared with radiotherapy significant differential volume-response after treatment with only.
    [Show full text]
  • Labelled Combretastatin A1P
    Synthesis of [13C]-labelled Combretastatin A1P By Rebecca Christina Collins A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy The University of Sheffield Faculty of Science Department of Chemistry Submission Date: September 2015 Contents Declaration iv Acknowledgements v Abbreviations vi Abstract xi 1. Introduction 1 1.1. Cancer treatment 1 1.2. Vascular Disrupting Agents 2 1.2.1. Tubulin and microtubules 4 1.2.2. Tubulin Inhibitors 5 1.3. Combretastatins 7 1.3.1. Combretastatins as vascular disrupting agents 9 1.4. Combretastatin Analogues 10 1.5. Synthesis of combretastatins 12 1.5.1. Synthesis of combretastatins by the Wittig reaction 12 1.5.2. Synthesis of combretastatins by Cross coupling reactions 14 1.5.3. Synthesis of combretastatins by Selective Reduction of 18 diarylalkynes 1.5.4. Synthesis of pro-drugs CA1P and CA4P 20 1.6. Combretastatin A1P metabolism 21 1.7. Molecular Imaging 27 1.8. Enhancing MR signal by hyperpolarisation 28 1.9. Applications of hyperpolarised MR 30 1.10. Hyperpolarisation considerations and techniques 32 1.10.1. Brute Force 33 1.10.2. Optical pumping 33 1.10.3. Para-Hydrogen induced polarisation 34 1.10.4. Dynamic nuclear polarisation 35 1.11. Dissolution-DNP experiment 35 1.12. Hyperpolarised substrates 37 1.12.1. 13C DNP probe development 38 1.13. Project Aims 40 ii 2. Synthesis of [13C]-Combretastatin A1P 41 2.1. T1 times of CA1P 41 2.2. Synthesis of core aromatic species 42 2.3. Synthesis of CA1P via Selective Reduction of diarylalkyne 50 2.4.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,135,581 B2 Agoston Et Al
    US007135581B2 (12) United States Patent (10) Patent No.: US 7,135,581 B2 Agoston et al. (45) Date of Patent: Nov. 14, 2006 (54) ANTIANGIOGENICAGENTS 4.212,864 T. 1980 Tax 4,307,086 12, 1981 Tax (75) Inventors: Gregory E. Agoston, Germantown, MD 4,444,767 4, 1984 Torelli et al. (US); Jamshed H. Shah, Brookeville, 4,522,758 6, 1985 Ward et al. 4.552,758 11, 1985 Murphy et al. MD (US); Kimberly A. Hunsucker, 4,634,705 1, 1987 DeBernardis et al. Germantown, MD (US); Victor S. 4,743,597 5, 1988 Javitt et al. Pribluda, Silver Spring, MD (US); 4,808.402 2, 1989 Leibovich et al. Theresa M. LaVallee, Rockville, MD 4,994.443 2, 1991 Folkman et al. (US); Shawn J. Green, Vienna, VA 5,001,116 3, 1991 Folkman et al. (US); Christopher J. Herbstritt, 5,135,919 8, 1992 Folkman et al. Rockville, MD (US); Xiaoguo H. 5,504,074 4, 1996 D'Amato et al. Zhan, Montgomery Village, MD (US); 5,521,168 5, 1996 Clark Anthony M. Treston, Rockville, MD 5,621,124 4, 1997 Seilz et al. (US) 5,629,340 5, 1997 Kuwano et al. 5,639,725 6, 1997 O'Reilly et al. (73) Assignee: Entremed, Inc., Rockville, MD (US) 5,643,900 7/1997 Fotsis et al. 5,661,143 8, 1997 D'Amato et al. (*) Notice: Subject to any disclaimer, the term of this 5,716.981 2, 1998 Hunter et al. patent is extended or adjusted under 35 5,733,876 3, 1998 O'Reilly et al.
    [Show full text]
  • Combretastatin A4 Conjugate for Solid Tumor Therapy
    Acta Biomaterialia 53 (2017) 179–189 Contents lists available at ScienceDirect Acta Biomaterialia journal homepage: www.elsevier.com/locate/actabiomat Full length article A poly(L-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor ⇑ Tianzhou Liu a, Dawei Zhang c, Wantong Song c, Zhaohui Tang c, , Jiaming Zhu a, Zhiming Ma a, ⇑ Xudong Wang a, Xuesi Chen c, Ti Tong b, a Department of Gastrointestinal Surgery, The Second Hospital of Jilin University, Changchun 130041, PR China b Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun 130041, PR China c Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China article info abstract Article history: Combretastatin A4 (CA4) is a leading agent in vascular disrupting strategies for tumor therapy. Although Received 1 September 2016 many small-molecule prodrugs of CA4 have been developed to improve its solubility, the overall thera- Received in revised form 30 January 2017 peutic efficiency is moderate. A key reason for this is the reversible effect that CA4 has on tubulin as well Accepted 1 February 2017 as its rapid clearance from plasma and tissues. In this study, we proposed a poly(L-glutamic acid)-CA4 Available online 3 February 2017 conjugate (PLG-CA4) nanomedicine to fulfill the requirements for fully liberating the potential of CA4 on tumor therapy. Enhanced accumulation and retention of CA4 in tumor tissue, especially, high distri- Keywords: bution and gradual release around tumor blood vessels resulted in prolonged vascular disruption and Vascular disrupting agents markedly enhanced therapeutic efficiency.
    [Show full text]
  • International Patent Classification: TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, A61K 31/09 (2006.01) A61K9/00 (2006.01) KM, ML, MR, NE, SN, TD, TG)
    ( International Patent Classification: TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, A61K 31/09 (2006.01) A61K9/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/05 (2006.01) C07C 39/23 (2006.01) A61K 31/352 (2006.01) C07C 43/295 (2006.01) Published: A61K 36/185 (2006.01) C07C 311/60 (2006.01) — with international search report (Art. 21(3)) A61K 47/10 (2017.01) C07D 311/80 (2006.01) (21) International Application Number: PCT/CA20 19/050166 (22) International Filing Date: 08 February 2019 (08.02.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/628,735 09 February 2018 (09.02.2018) US (71) Applicant: NEUTRISCI INTERNATIONAL INC. [CA/CA]; Suite 1A, 4015 - 1st Street SE, Calgary, Alberta T2G 4X7 (CA). (72) Inventors: REHMAN, Glen; c/o NeutriSci International Inc., Suite 1A - 4015 - 1st Street SE, Calgary, Alberta T2G 4X7 (CA). BUSHFIELD, Keith Patrick; c/o NeutriSci In¬ ternational Inc., Suite 1A - 4015 - 1st Street SE, Calgary, Alberta T2G 4X7 (CA). (74) Agent: ROACH, Mark; Flicks & Associates, 709 Main Street, Suite 300, Canmore, Alberta T1W 2B2 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW,KZ, LA, LC, LK, LR, LS, LU, LY,MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Synthesis and Biological Properties of Bioreductively Targeted Nitrothienyl Prodrugs of Combretastatin A-4
    2886 Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4 Peter Thomson,1 Matthew A. Naylor,1 cytoskeleton of the endothelial cells lining the tumor Steven A. Everett,1 Michael R.L. Stratford,1 vasculature (6–8). When this tubulin structure is disrupted, Gemma Lewis,1 Sally Hill,1 Kantilal B. Patel,1 the endothelial cells change shape from flat to round, Peter Wardman,1 and Peter D. Davis2 impeding blood flow through the capillary, starving the tumor of nutrients, and causing tumor cell death (8–10). 1University of Oxford, Gray Cancer Institute, Mount Vernon Preclinical animal model studies and subsequent clinical Hospital, Northwood, Middlesex, United Kingdom and 2 trials have shown that the drug drastically reduces blood Angiogene Pharmaceuticals Ltd., The Magdalen Centre, Oxford flow in tumors (11). Phase I human cancer clinical trials of Science Park, Oxon, United Kingdom the sodium CA4 phosphate prodrug (2; Fig. 1) have been successfully completed (12, 13) and the drug is currently Abstract undergoing phase II trials. 1 Nitrothienylprop-2-yl ether formation on the 3¶-phenolic The discovery of prompted the synthesis of many position of combretastatin A-4 (1) abolishes the cytotox- structural variations as improved vascular targeting agents icity and tubulin polymerization-inhibitory effects of the (14–17). However, the combretastatins also have powerful drug. 5-Nitrothiophene derivatives of 1 were synthesized antiproliferative activity against cancer cell lines in vitro followingmodel kinetic studies with analogouscoumarin (3, 14, 18–25), and it is thought that this is due to an derivatives, and of these, compound 13 represents a antimitotic action brought about by inhibition of tubulin promisingnew lead in bioreductively targetedcytotoxic polymerization.
    [Show full text]
  • Exploring Diverse-Ring Analogues on Combretastatin A4 (CA-4) Olefin As Microtubule-Targeting Agents
    International Journal of Molecular Sciences Article Exploring Diverse-Ring Analogues on Combretastatin A4 (CA-4) Olefin as Microtubule-Targeting Agents 1, 1, 2 2 3 Ming-Yu Song y, Qiu-Rui He y, Yi-Lin Wang , Hao-Ran Wang , Tian-Cheng Jiang , Jiang-Jiang Tang 1,* and Jin-Ming Gao 1 1 Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China; [email protected] (M.-Y.S.); [email protected] (Q.-R.H.); [email protected] (J.-M.G.) 2 College of Innovation and Experiment, Northwest A&F University, Yangling 712100, China; [email protected] (Y.-L.W.); [email protected] (H.-R.W.) 3 College of Food Science and Engeering, Northwest A&F University, Yangling 712100, China; [email protected] * Correspondence: [email protected]; Tel.: +86-2987-09-2662 These authors contributed equally to this work. y Received: 15 February 2020; Accepted: 4 March 2020; Published: 6 March 2020 Abstract: Combretastatin-4 (CA-4) as a tubulin polymerization inhibitor draws extensive attentions. However, due to its weak stability of cis-olefin and poor metabolic stability, structure modifications on cis-configuration are being performed. In this work, we constructed a series of novel CA-4 analogues with linkers on olefin containing diphenylethanone, cis-locked dihydrofuran, α-substituted diphenylethanone, cyclobutane and cyclohexane on its cis-olefin. Cytotoxic activity of all analogues was measured by an SRB assay. Among them, compound 6b, a by-product in the preparation of diphenylethanone analogues, was found to be the most potent cytotoxic agents against HepG2 cells with IC50 values of less than 0.5 µM.
    [Show full text]
  • Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin
    Vol. 11, 1527–1533, February 15, 2005 Clinical Cancer Research 1527 Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin Joshua H. Bilenker,1 Keith T. Flaherty,1 Pharmacokinetic/pharmacodynamic modeling permitted the Mark Rosen,1 Lisa Davis,2 Maryann Gallagher,1 inference that altered carboplatin pharmacokinetics caused James P. Stevenson,1 Weijing Sun,1 David Vaughn,1 the increment in platelet toxicity. Bruce Giantonio,1 Ross Zimmer,1 Mitchell Schnall,1 and Peter J. O’Dwyer1 INTRODUCTION 1University of Pennsylvania Cancer Center and 2Philadelphia College of Combretastatin A-4 Phosphate (CA4P) is a synthetic, Pharmacy, University of the Sciences in Philadelphia, Philadelphia, phosphorylated prodrug of the natural product combretastatin Pennsylvania A-4 (CA4). The combretastatins are heterocyclic plant alkaloids derived originally from the bark of the African bush willow, ABSTRACT Combretum caffrum, and have been investigated as anticancer agents because of their activity as inhibitors of tumor blood flow Purpose: Preclinical evidence of synergy led to a phase I (1, 2). In vitro, CA4 is a strong tubulin-binding agent that trial employing combretastatin A-4 phosphate (CA4P), a prevents tubulin polymerization and is toxic to actively novel tubulin-binding antivascular drug, in combination proliferating vascular endothelial cells at concentrations in the with carboplatin. low micromolar range (3–6). CA4 is also cytotoxic to a variety Experimental Design: Based on preclinical scheduling of human cancer cell lines. In some studies, activity was studies, patients were treated on day 1 of a 21-day cycle. observed at concentrations higher than those toxic to endothelial Carboplatin was given as a 30-minute i.v.
    [Show full text]
  • Combretastatin A-4-Phosphate Effectively Increases Tumor Retention of the Therapeutic Antibody, 131I-A5B7, Even at Doses That Are Sub-Optimal for Vascular Shut-Down
    453-460 3/1/07 13:40 Page 453 INTERNATIONAL JOURNAL OF ONCOLOGY 30: 453-460, 2007 453 Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down KATHARINE J. LANKESTER1, ROSS J. MAXWELL1, R. BARBARA PEDLEY2, JASON L. DEARLING2, UZMA A. QURESHI2, ETHAAR EL-EMIR2, SALLY A. HILL1 and GILLIAN M. TOZER1,3 1Gray Cancer Institute, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middx, HA6 2JR, 2Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School Hampstead Campus, UCL, London, NW3 2PF, UK Received September 7, 2006; Accepted October 30, 2006 Abstract. Radioimmunotherapy using 131I-A5B7, an anti- dose response, all three dose levels increased tumor retention CEA antibody, in combination with the vascular disrupting of radio labeled antibody to a similar degree. These results agent, combretastatin A4-phosphate (CA-4-P, 200 mg/kg), demonstrate that moderate tumor blood flow reduction has produced tumor cures in SW1222 colorectal xenografts. following antibody administration is sufficient to improve CA-4-P causes acute tumor blood vessel shutdown, which tumor antibody retention. This is encouraging for the com- can be monitored in clinical trials using dynamic contrast bination of CA-4-P and 131I-A5B7 in clinical trials. enhanced magnetic resonance imaging (DCE-MRI). The purpose of this study was to determine the magnitude of Introduction the anti-vascular effect of CA-4-P in the SW1222 tumor, at 200 mg/kg and at lower, more clinically relevant doses, using In radioimmunotherapy (RIT), a radiolabeled antibody localizes conventional assays; relate effects to changes in DCE-MRI to a tumor-associated antigen, thus targeting radiation directly parameters and determine the corresponding effects on tumor to a tumor.
    [Show full text]
  • Novel Cis-Restricted Β-Lactam Combretastatin A-4 Analogues Display Anti-Vascular and Anti-Metastatic Properties in Vitro
    Technological University Dublin ARROW@TU Dublin School of Chemical and Pharmaceutical Articles Sciences 2013 Novel Cis-restricted β-lactam Combretastatin A-4 Analogues Display Anti-vascular and Anti-metastatic Properties in Vitro Seema M. Nathwani Trinity College Dublin Ireland, [email protected] Lisa M. Greene Trinity College Dublin Ireland, [email protected] Linda Hughes Trinity College Dublin Ireland See next page for additional authors Follow this and additional works at: https://arrow.tudublin.ie/scschcpsart Part of the Biochemistry Commons, Medicinal Chemistry and Pharmaceutics Commons, Molecular Biology Commons, Organic Chemicals Commons, and the Pharmacology Commons Recommended Citation Nathwani, S. et al (2013). Novel cis-restricted β-lactam combretastatin A-4 analogues display anti- vascular and anti-metastatic properties in vitro. Oncology Reports, 2013, 29(2), pp. 585-594. doi:10.3892/ or.2012.2181 This Article is brought to you for free and open access by the School of Chemical and Pharmaceutical Sciences at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact [email protected], [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License Authors Seema M. Nathwani, Lisa M. Greene, Linda Hughes, Miriam Carr, Niamh O'Boyle, Susan McDonnell, Mary J. Meegan, and Daniela M. Zisterer This article is available at ARROW@TU Dublin: https://arrow.tudublin.ie/scschcpsart/70 ONCOLOGY REPORTS 29: 585-594, 2013 Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro SEEMA-MARIA NATHWANI1, LINDA HUGHES2, LISA M.
    [Show full text]